SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2021.04.14 | 22:06 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - HTML (w)

2021.04.09 | 22:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Two New Nominees for Election to Board of Directors - HTML (w)

2021.04.08 | 13:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Bio-Thera Solutions Announce Commercialization and License Agreement for Proposed Biosimilar Currently in Phase 3 With the Potential to Treat Moderate to Severe Rheumatoid Arthritis - HTML (w)

2021.04.07 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce The European Commission Grants Marketing Authorization for New Subcutaneous Administration of TYSABRI® (natalizumab) to Treat Relapsing-Remitting Multiple Sclerosis - HTML (w)

2021.03.04 | 13:47 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Plans to Build a New, State-of-the-Art Gene Therapy Manufacturing Facility in Research Triangle Park, North Carolina - HTML (w)

2021.02.24 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Life Science Cares and Biogen Foundation Help Launch Food For Free’s Just Eats Program - HTML (w)

2021.02.11 | 14:03 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Biogen Announces the Expiration Date Results of Its Cash Tender Offer - HTML (w)

2021.02.11 | 14:00 | Permanent Information Releases / Sales and Revenues

English version HTML (w) Mail

puce Biogen Announces the Expiration Date Results of Its Private Exchange Offer - HTML (w)

2021.02.10 | 19:02 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces the Pricing Terms of its Cash Tender Offer - HTML (w)

2021.02.10 | 19:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces the Pricing Terms of Its Private Exchange Offer - HTML (w)

2021.02.04 | 15:02 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only - HTML (w)

2021.02.04 | 15:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors - HTML (w)

2021.02.01 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis - HTML (w)

2021.01.29 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab - HTML (w)

2021.01.11 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 / Doc nb : 132